268 related articles for article (PubMed ID: 25342375)
41. Sjögren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options.
Birt JA; Tan Y; Mozaffarian N
Clin Exp Rheumatol; 2017; 35(1):98-107. PubMed ID: 27749234
[TBL] [Abstract][Full Text] [Related]
42. Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions.
Brito-Zerón P; Sisó-Almirall A; Bové A; Kostov BA; Ramos-Casals M
Expert Opin Pharmacother; 2013 Feb; 14(3):279-89. PubMed ID: 23346917
[TBL] [Abstract][Full Text] [Related]
43. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
[TBL] [Abstract][Full Text] [Related]
44. Sjögren's syndrome. Controversies and progress.
Fox RI
Clin Lab Med; 1997 Sep; 17(3):431-44. PubMed ID: 9316767
[TBL] [Abstract][Full Text] [Related]
45. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
46. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
Guzman Moreno R
Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
[TBL] [Abstract][Full Text] [Related]
47. [Sjögren's syndrome: a new approach to treatment].
Rossier V; Bart PA; Spertini F
Rev Med Suisse; 2012 Apr; 8(337):843-7. PubMed ID: 22594008
[TBL] [Abstract][Full Text] [Related]
48. Present and novel biologic drugs in primary Sjögren's syndrome.
Fasano S; Isenberg DA
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):167-174. PubMed ID: 31025931
[TBL] [Abstract][Full Text] [Related]
49. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
50. Management of extraglandular manifestations of primary Sjögren's syndrome.
Wu JJ; Carsons SE
Oral Maxillofac Surg Clin North Am; 2014 Feb; 26(1):101-9. PubMed ID: 24287198
[TBL] [Abstract][Full Text] [Related]
51. Targeting IL-1 in Sjögren's syndrome.
Yamada A; Arakaki R; Kudo Y; Ishimaru N
Expert Opin Ther Targets; 2013 Apr; 17(4):393-401. PubMed ID: 23320392
[TBL] [Abstract][Full Text] [Related]
52. Development of autoimmune arthritis with aging via bystander T cell activation in the mouse model of Sjögren's syndrome.
Kobayashi M; Yasui N; Ishimaru N; Arakaki R; Hayashi Y
Arthritis Rheum; 2004 Dec; 50(12):3974-84. PubMed ID: 15593201
[TBL] [Abstract][Full Text] [Related]
53. Clinical efficacy of leflunomide in primary Sjogren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression.
Bikker A; van Woerkom JM; Kruize AA; van der Wurff-Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA
Ann Rheum Dis; 2012 Dec; 71(12):1934-41. PubMed ID: 22563027
[TBL] [Abstract][Full Text] [Related]
54. Will targeting B cells be the answer for Sjögren's syndrome?
Looney RJ
Arthritis Rheum; 2007 May; 56(5):1371-7. PubMed ID: 17469093
[No Abstract] [Full Text] [Related]
55. Sjögren's syndrome: where do we stand, and where shall we go?
Cornec D; Jamin C; Pers JO
J Autoimmun; 2014 Jun; 51():109-14. PubMed ID: 24612946
[TBL] [Abstract][Full Text] [Related]
56. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
57. Classification criteria and treatment modalities in primary Sjögren's syndrome.
Fazaa A; Bourcier T; Chatelus E; Sordet C; Theulin A; Sibilia J; Gottenberg JE
Expert Rev Clin Immunol; 2014 Apr; 10(4):543-51. PubMed ID: 24646087
[TBL] [Abstract][Full Text] [Related]
58. Biological therapies of autoimmune diseases.
Kourbeti IS; Boumpas DT
Curr Drug Targets Inflamm Allergy; 2005 Feb; 4(1):41-6. PubMed ID: 15720235
[TBL] [Abstract][Full Text] [Related]
59. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome.
Fox RI; Kang HI; Ando D; Abrams J; Pisa E
J Immunol; 1994 Jun; 152(11):5532-9. PubMed ID: 8189070
[TBL] [Abstract][Full Text] [Related]
60. Biologic therapy for rheumatoid arthritis in developing countries--a place for non-TNF inhibitors as first-line treatment?
Tikly M; Hodkinson B; Dheda K
Rheumatology (Oxford); 2015 Feb; 54(2):208-9. PubMed ID: 24692577
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
